REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) today announces the US government’s approval of the transfer (“novation”) of the GC-072 contract to Emergent BioSolutions Inc. (NYSE: EBS). This triggers a payment of USD 4 million to Evolva, following an initial upfront payment of USD 1.5 million in December 2014. This does not change the revenue guidance for 2015. In December 2014, Emergent acquired Evolva’s anti-bacterial programme, the EV-035 series in a transaction worth up to USD 70